Every successful therapy can change a person's life. It can help patients live longer, live better, and spend less time managing the burden of treatment. We believe oligonucleotides have the potential to make that difference by targeting disease with greater precision. Our goal is to develop effective, well-tolerated medicines that improve patients' lives and make treatment easier to live with.
Modern medicine has transformed the treatment of many diseases, but better outcomes often come with unwanted side effects. For many patients, the burden of treatment becomes part of the disease itself. When therapies cannot fully distinguish between healthy and diseased cells, unwanted effects can limit treatment, reduce quality of life, and increase the overall burden of care. That is why improving precision has become one of the defining goals of modern drug development. ESiNAR-X® was developed to improve precision without compromising therapeutic potential. By leveraging the selectivity and potency of our oligonucleotides, we aim to develop therapies that combine strong biological activity with improved tolerability, helping patients experience the benefits of treatment with a reduced burden of side effects.
Targeted therapeutics represent one of the fastest-growing areas in biopharmaceutical development. The market is expected to reach €170B by 2030, driven by advances in molecular biology and more precise treatment approaches. Oligonucleotide therapies are an important part of this evolution, enabling highly specific approaches to disease treatment. ESiNAR-X® is designed to build on this opportunity by combining precision, potency, and tolerability to support the development of differentiated therapies across multiple disease areas. It doesn't just compete in the market; it expands it.
While targeted therapies have transformed cancer care, their success is often limited by resistance, toxicity, and the inability to selectively eliminate disease-driving cells. In chronic myeloid leukemia (CML), around 30% of patients experience resistance or intolerance to tyrosine kinase inhibitors (TKIs). ASP210 targets BCR-ABL1 at the RNA level and has shown reduced leukemic burden in preclinical CML models, while also demonstrating remarkable activity in TKI-resistant CML cells.
As viruses continue to evolve, new antiviral approaches are needed to stay ahead. ESiNAR-X® enables RNA-targeted therapies designed to address viral replication at its source. ASC1R, our lead program, has demonstrated potent antiviral activity and strong tolerability in preclinical SARS-CoV-2 studies.
Chronic kidney disease continues to progress in many patients despite available treatments. ASPER2 is designed to target renal fibrosis, a key driver of kidney damage, with the goal of slowing disease progression and preserving kidney function before irreversible failure occurs.
Patent granted in 2020 · ESiNAR-X® · a single platform with applications spanning multiple therapeutic areas and biological targets.
Are you an individual or organisation who would like to back our science? You can support our research through our partner platform MediScine.
Whether you are an investor, a research partner or a future colleague — there is a place for you in the next chapter of safe oligonucleotide therapeutics.
